News Classic

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Wilmington, Delaware , Oct. 17, 2024 (GLOBE NEWSWIRE) — Allied Market Research published a report, titled, “Automotive Aluminum Market by Form (Sheet, Plate, Bar, Tube and Others), Vehicle Type (Light Commercial Vehicles, Heavy Commercial Vehicles, Passenger Cars and Others), and Application (Hood, Pillars, Hinges, Motors, Sunroof Railings and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033″. According to the report, the automotive aluminum market was valued at $26.2 billion in 2023, and is estimated to reach $60.6 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033. 

Prime determinants of growth 

Advancements in aluminum alloys are pivotal in fueling the demand for automotive aluminum. These advancements encompass innovations in alloy compositions, manufacturing methods and treatments all geared towards augmenting the properties and functionality of aluminum utilized in automotive applications. By continually refining aluminum alloys manufacturers produce materials with true attributes to address diverse automotive needs. For instance, certain alloys are crafted to exhibit exceptional formability facilitating the creation of complicated shapes and designs in vehicle parts. In addition, other alloys are tailored to bolster corrosion resistance, thereby ensuring prolonged durability and resilience across different environmental settings. Such tailored properties make aluminum alloys indispensable in meeting the exacting standards of the automotive industry, driving the demand for automotive aluminum market growth. 

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/1978  

Report coverage & details: 

The sheet segment maintains its dominance by 2033. 

By form, the sheet segment held the highest market share in 2023 and is estimated to maintain its leadership status throughout the forecast period. Sheet is extensively utilized in automotive body panels, closures such as hoods and doors, and structural components due to its lightweight nature, formability, and corrosion resistance. The use of aluminum sheet allows for significant weight reduction in vehicles, contributing to improved fuel efficiency and performance. 

The light commercial vehicles segment is expected to possess the highest market share till 2033. 

By vehicle type, light commercial vehicles segment held the highest market share in 2023 and is estimated to dominate during the forecast period. Aluminum is commonly utilized in the construction of light commercial vehicles, such as vans, pickups, and smaller trucks. Light commercial vehicles often prioritize factors such as fuel efficiency, payload capacity, and maneuverability, all of which benefit from the lightweight properties of aluminum. Aluminum is frequently employed in body panels, chassis components, and structural reinforcements in light commercial vehicles, contributing to weight reduction and improved performance. 

Procure Complete Report (340 Pages PDF with Insights, Charts, Tables, and Figure https://www.alliedmarketresearch.com/checkout-final/automotive-aluminum-market 

The hoods segment is expected to possess the highest market share till 2033. 

Based on the application, hoods segment held the highest market share in 2023 and is estimated to dominate during the forecast period. Hoods are increasingly common in modern vehicles thanks to their lightweight properties, which play a crucial role in enhancing fuel efficiency and handling. Automakers are opting for aluminum hoods to achieve significant weight reduction compared to traditional steel hoods, making aluminum the preferred material for boosting overall vehicle performance. Moreover, the use of aluminum hoods supports the structural integrity and safety of the vehicle. Despite being lighter, aluminum hoods maintain the necessary strength and durability to protect the engine compartment and absorb impact in the event of a collision. This combination of lightweight efficiency and robust performance makes aluminum hoods an ideal component for modern automotive design. 

Asia-Pacific is expected to experience fastest growth throughout the forecast period. 

Based on region, Asia-Pacific has emerged as the fastest-growing market for automotive aluminum in terms of revenue. The lightweight and recyclable properties of aluminum present promising solutions for improving fuel efficiency and reducing emissions within the automotive sector. As countries in Asia-Pacific experience rapid urbanization and a surge in vehicle demand, the necessity for sustainable and efficient automotive materials becomes increasingly critical. Automotive aluminum, with its capacity to lower vehicle weight and enhance performance while reducing environmental impact, perfectly aligns with the region’s sustainability goals. In addition, the abundant availability of raw materials and advanced manufacturing capabilities across many Asia-Pacific nations is fostering the widespread adoption of automotive aluminum, further driving market growth in the region. 

Want to Access the Statistical Data and Graphs, Key Players’ Strategies: https://www.alliedmarketresearch.com/automotive-aluminum-market/purchase-options  

Leading Market Players: – 

• Nippon Light Metal Holdings Co., Ltd 

• Vedanta Aluminium & Power 

The report provides a detailed analysis of these key players in the global automotive aluminum market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

About Us 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. 

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. 

Contact: 

David Correa 

United States 

1209 Orange Street, 

Corporation Trust Center, 

Wilmington, New Castle, 

Delaware 19801 USA. 

Int’l: +1-503-894-6022 

Toll Free: +1-800-792-5285 

Fax: +1-800-792-5285  

help@alliedmarketresearch.com 
Web: www.alliedmarketresearch.com 
Allied Market Research Blog: https://blog.alliedmarketresearch.com  
Blog: https://www.newsguards.com/ 
Follow Us on | Facebook | LinkedIn | YouTube | 

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Westford, USA, Oct. 17, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Wound Care Market will attain the value of USD 16.32 Billion by 2031, with a CAGR of 3.1% during the forecast period (2024-2031). The growth of wound care market can be attributed to factors such as increasing aging population, increasing incidence of chronic wounds, advancements in wound care technology. Furthermore, there is growing awareness of its importance that wound management and availability of advanced wound care products drives market growth. 

Wound Care Market Overview:  

To Learn More About This Report, Request a Free Sample Copy – https://www.skyquestt.com/sample-request/wound-care-market  

Wound Care Market Segmental Analysis

The Global Wound Care Market is segmented into Product, Application, End Use, and Region.

Based on Product, the market is segmented into Advanced Wound Dressing, Surgical Wound Dressing, and Traditional Wound Dressing.

Based on Application, the market is segmented into Chronic Wound and Acute Wound.

Based on End Use, the market is segmented into Hospitals, Specialty Clinics, Home Healthcare, Physician’s Office, Nursing Homes, and Others.

By Region, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America. 

Institutional Sales Segment to Dominate Due to High Volume of Patients in Hospitals and Clinics 

The institutional sales segment is dominating in the market. Manufacturers of wound care products can also sell the products directly to healthcare providers, such as hospitals and clinics, or to patients through direct-to-consumer marketing. This approach can provide significant potential on how it is distributed to enable manufacturers to build relationships with their customers. Marketing companies consist of direct distributors and specialists. Hospitals, clinics, wound care centers, and other health care facilities, such as nursing homes, long-term care facilities, research centers, and maternity care centers, often have contracts and relationships that it lasts longer with the distributors and manufacturers. 

Home Healthcare Segment to Drive Market Due to Introduction of Single-use NPWT Systems 

The home healthcare segment is expected to grow at the fastest pace at a CAGR of 5.51% during the forecast period. During the pandemic outbreak, home healthcare wound care products were more in demand. Wound care in home care centers begins primarily with the introduction of single-use NPWT systems. These devices are small, portable and easy to use. In addition, the cost of such wound healing also encourages patients to opt for home care facilities during their hospital stay. 

Get Customization on this Report for Specific Research Solutions: https://www.skyquestt.com/speak-with-analyst/wound-care-market

Asia Pacific is Growing Due to Increasing Incidence of Chronic Diseases 

The Asia Pacific region is estimated to witness the highest growth in the wound care market at a CAGR of 4.8% during the forecast period. The presence of developing countries such as China, India and Japan are expected to drive the market growth in this region. This can be attributed to the increasing lifestyle changes that are contributing to the increased incidence of chronic diseases in the region. Furthermore, technological advancement, increasing age population, increasing incidence of chronic diseases like diabetes & cancer are expected to boost the growth of the regional market. Thus, Asia Pacific is expected to witness the fastest growth during the forecast period due to the aforementioned factors.   

Drivers  

• Growing Prevalence of Chronic Diseases 

• Technological Advancements 

• Rise in the Aging Population 

Restraints  

• Limited Awareness in Developing Regions 

• Regulatory Hurdles and Approvals 

• High Cost of Advanced Wound Care Products 

Prominent Players in Wound Care Market   

• Smith & Nephew
• Mölnlycke Health Care AB
• ConvaTec Group PLC
• Ethicon (Johnson & Johnson)
• Baxter International
• URGO Medical
• Coloplast Corp.
• Medtronic
• 3M
• Derma Sciences Inc. (Integra LifeSciences)
• Medline Industries
• Advancis Medical
• B. Braun Melsungen AG 

Take Action Now: Secure Your Wound Care Market Today – https://www.skyquestt.com/buy-now/wound-care-market

Key Questions Answered in Wound Care Market Report  

• How big is the Global Wound Care Market?  

• What are the key drivers of Global Wound Care Market size?  

• Which is the fastest growing region in the Global Wound Care Market?  

This report provides the following insights:  

Analysis of key drivers (growing prevalence of chronic diseases, technological advancements, rise in the aging population), restraints (regulatory hurdles and approvals, high cost of advanced wound care products), opportunities (rising demand for home healthcare solutions), influencing the growth of Wound Care Market.  

• Market Dynamics: Comprehensive information about the various products offered by the dominant players in the Wound Care Market.  

• Product Development/Innovation: An overview of emerging trends, R&D activities and product launches in the Wound Care Market.   

• Market Growth: Detailed information on profitable growing industries.   

• Market Trends: Complete information about new products, emerging geographical areas and recent developments in the market.  

• Competitive Analysis: An in-depth analysis of the market segments, growth strategies, revenue analysis, and products of the key market players.  

Read Wound Care Market Report Today – https://www.skyquestt.com/report/wound-care-market

Checkout More Related Studies Published by SkyQuest Technology:

Advanced Wound Care Market is growing at a CAGR of 5.4% in the forecast period (2024-2031)

Pressure Ulcers Treatment Market is growing at a CAGR of 5.2% in the forecast period (2024-2031)

Europe Home Healthcare Market is growing at a CAGR of 7.6% in the forecast period (2024-2031)

Low Trauma/Skin Friendly Adhesives Market is growing at a CAGR of 6.7% in the forecast period (2024-2031)

Europe Advanced Wound Care Market is growing at a CAGR of 6% in the forecast period (2024-2031)

About Us:  

SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.  

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.  

Contact Us:  

Mr. Jagraj Singh  

Skyquest Technology  

1 Apache Way,  

Westford,  

Massachusetts 01886  

USA (+1) 351-333-4748  

Email: sales@skyquestt.com  

Visit Our Website: https://www.skyquestt.com/ 

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms

SPN-820 was well-tolerated with few adverse events

SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression

Company to host webcast today at 4:30 p.m. ET to discuss the topline data

Topline results from Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression expected first-half 2025

ROCKVILLE, Md., Oct. 17, 2024 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder. The study examined the safety and tolerability of SPN-820 2400 mg given once every 3 days as an adjunctive treatment to the current baseline antidepressant therapy, as well as assessed the rapid onset of improvement in depressive symptoms. The analysis is based on 40 enrolled subjects, of which 38 completed the 10-day treatment period.

Summary of the Data

• Clinically meaningful improvement of –6.1 at two hours and –9.6 at Day 10 on the Hamilton Depression Rating Scale-6 Items (HAM-D6) total score.
• Clinically meaningful improvement of –16.6 at four hours and –22.9 at Day 10 on the Montgomery Åsberg Depression Rating Scale (MADRS) total score.
• Suicidal ideation decreased by 80% (12.5% with suicidal ideation at baseline decreased to 2.6% with suicidal ideation at Day 10).
• SPN-820 was well-tolerated with few adverse events (AEs) and had acceptable tolerability with a discontinuation rate of 2.5% due to AEs.
• Most common AEs related to the drug included headache, nausea, somnolence, and dizziness. Additional AEs such as cognitive disorder, dry mouth, fatigue, nasal decongestion, and paresthesia oral were observed.

“These Phase 2a data underscore our belief that SPN-820 has the potential as a novel treatment option for patients with depression, with the opportunity to decrease symptoms quickly and without certain burdensome side effects,” said Jack Khattar, President and CEO of Supernus. “We expect to complete enrollment in the Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression in November of this year, with topline results expected in the first half of 2025.”

Webcast Details

Supernus will host a conference call and webcast today, October 17, 2024, at 4:30 p.m. ET to discuss these topline results. A live webcast with presentation slides will be available via this webcast link or in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/Investors. Following management’s prepared remarks and discussion of the interim trial results, the call will open for questions.

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company’s Investor Relations website at www.supernus.com/Investors. The webcast will be available on the Company’s website for 60 days following the live call.

About SPN-820

SPN-820 is a first-in-class, orally active small molecule that increases the brain mechanistic target of rapamycin complex 1 (mTORC1) mediated synaptic function intracellularly. SPN-820 is being developed to provide a rapid-onset antidepressant response via oral administration for adult patients with depression. The compound has a novel mechanism of action that enhances synaptic activity and cellular metabolism in the brain and has demonstrated a rapid onset of action (signal at two hours) in early clinical studies. SPN-820 is expected to provide rapid antidepressant efficacy without potential dissociative side effects. A Phase 2b clinical study of SPN-820 in approximately 227 adult patients with treatment-resistant depression is ongoing.

About the SPN-820 Phase 2a Clinical Study

The study is a Phase 2a open-label study in 40 subjects with major depressive disorder (MDD). The primary objective of the study is to assess efficacy in MDD, as well as onset of efficacy and safety.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

For more information, please visit www.supernus.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s reporting on preliminary and exploratory open label clinical study on SPN-820, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase net revenue; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s ability to conduct and progress product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates including SPN-820; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates including SPN-820; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates including SPN-820; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

CONTACTS:

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591

or

INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
(443) 213-0505
peter.vozzo@westwicke.com

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Vice President Kamala Harris is facing criticism over a new Medicare policy that’s stirring up controversy. Critics accuse her of backtracking on promises to safeguard the Medicare trust fund, sparking a fiery debate about whether the administration’s recent moves are helping or hurting the nation’s seniors.

Harris recently reassured the public that Medicare is a priority, telling AARP, “I will always fight to protect and strengthen Medicare for this and future generations.” She emphasized that big corporations and wealthy individuals must step up and pay their fair share, which she believes will help sustain critical programs like Medicare.

Don’t Miss:

But critics aren’t buying it. According to the latest Congressional Budget Office (CBO) analysis, a program introduced by the Centers for Medicare and Medicaid Services (CMS) to keep premiums low could cost taxpayers over $21 billion in the next three years.

This demonstration project, as it’s called, was designed to stabilize Medicare Part D premiums, which are set to rise sharply. Some, however, view it as a ploy to shield the administration from political fallout.

The plan stems from the Inflation Reduction Act, a bill to reduce drug costs for Medicare recipients. While the intent sounds good on paper, it comes with a significant catch: insurance companies will likely hike premiums substantially soon.

Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do — to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.

With the average bids for Part D plans expected to triple by 2025, many argue that the administration’s subsidy plan is just a short-term patch on a long-term problem.

Stephen Moore, co-founder of the Heritage Foundation, didn’t mince words. “More highway robbery from the Dems on the Medicare trust fund,” he said, echoing concerns that the government is siphoning off money meant to protect seniors’ health care to fund other initiatives.

Sen. Chuck Grassley, a key Republican voice, was equally critical. He suggested that instead of facing the consequences of their policies, Democrats are using taxpayer dollars to mask the impact.

See Also: Many are using this retirement income calculator to check if they’re on pace — here’s a breakdown on how on what’s behind this formula.

“This nonpartisan CBO analysis confirms CMS’s cost-shifting plan is a dishonest election year gimmick to cover up those consequences,” Grassley said in a statement, calling the move an attempt to “artificially” lower premiums in time for the election.

Story continues

The backlash on social media was swift. According to the advocacy group Commitment to Seniors, Harris has violated her pledge to secure Medicare.

They argue that this short-term fix could have long-term consequences for the trust fund, putting future generations at risk. “Seniors beware,” they wrote, warning of potential threats to the program the Vice President claimed she was protecting.

On the other side of the debate, administration defenders argue that the program provides necessary relief in an inflationary climate where drug prices and premiums are skyrocketing.

They emphasize that the Medicare trust fund still has safeguards in place and that the additional costs are a small price to pay for ensuring seniors don’t face crippling medical bills.

Read Next:

Up Next: Transform your trading with Benzinga Edge’s one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today’s competitive market.

Get the latest stock analysis from Benzinga?

This article Medicare Trust Fund Under Fire: Critics Accuse VP Harris Of ‘Highway Robbery’ For Allegedly ‘Violating’ Vital Healthcare Resources originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.